Peter Pitts

Peter Pitts, President of the Center for Medicine in the Public Interest and former FDA Associate Commissioner, dives into the unchecked dangers of compounded GLP-1 medications. He critiques the FDA's regulatory gaps and highlights the risks posed by unregulated foreign supply chains. The conversation tackles ethical concerns surrounding corporate funding and the pitfalls of 'phony personalization' in treatment. Pitts debates the future of GLP-1 regulations and the potential for more stringent enforcement or outright bans.